Cancer Research Technology
Log in Register
Menu

Anti-CD55, Recombinant [BU14]

Info

Catalogue Number 153263
Applications FACS IP
Antigen/Gene or Protein Targets CD55 (CD97 ligand)
Synonyms CD55 Molecule (Cromer Blood Group); CD55 Molecule; Decay Accelerating Factor For Complement (Cromer Blood Group); CD55 Antigen; DAF; CR; Decay Accelerating Factor For Complement; CROM; TC
Reactivity Human
Relevance CD97 is a member of the epidermal growth factor-seven transmembrane family. It affects tumour aggressiveness by binding its cellular ligand CD55 and exhibits adhesive properties. Previous studies have shown that CD97 and CD55 are involved in the dedifferentiation, migration, invasiveness and metastasis of tumours.
Host Mouse
Subclass IgG1
Formulation PBS
Concentration 1mgml-1
Research Area Immunology
Notes Recombinant monoclonal antibody produced from the original monoclonal cell line. Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma.

Five products based on this clone:
- Anti-CD55 [BU14], Mouse IgG1, Kappa
- Anti-CD55 [BU14], Rabbit IgG, Kappa
- Anti-CD55 [BU14], Human IgG4-S228P, Kappa
- Anti-CD55 [BU14], Human IgG1, Kappa
- Anti-CD55 [BU14], Human IgG1, Kappa, engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors

References

There are 1 reference entries for this reagent.

View All References

References: 1 entry

Original hybridoma first published in: Ling et al. 1998. Clin Exp Immunol. 113(3):360-6. PMID: 9737663.


Add a reference

References: 1 entry

Original hybridoma first published in: Ling et al. 1998. Clin Exp Immunol. 113(3):360-6. PMID: 9737663.


Add a reference

Inventor Information